Adapted Physical Activity in Patients With Resected Pancreatic Cancer (APACaPOp PRODIGE-56 Study): a National Multicenter Randomized Controlled Phase II Trial
GERCOR - Multidisciplinary Oncology Cooperative Group
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically proven PDAC
Complete macroscopic resection (R0 or R1 resection)
Patients randomized within 12 weeks of surgery
No evidence of malignant ascites, liver metastasis, spread to other distant abdominal organs, peritoneal metastasis, spread to extra-abdominal organs
Sufficient recovery from the operation and fit to take part in the trial
Able to attend for administration of the adjuvant CT
ECOG PS 0-2
Age ≥ 18 years
Life expectancy \> 3 months
Dated and signed informed consent
Registration in a national health care system (CMU included).
You may not be if
Macroscopically remaining tumor (R2 resection or TNM stage IV disease)
Histology other than PDAC
Cardiovascular, respiratory, psychiatric, musculoskeletal, or neurological condition contra-indicating exercise practice
Pregnancy or breastfeeding
Protected adults (individuals under guardianship by court order). Note: participation to another concomitant clinical trial is allowed but the patient must inform and get an authorization from the Investigator.
Clareo Health | Adapted Physical Activity in Patients With Resected Pancreatic Cancer (APACaPOp PRODIGE-56 Study): a National Multicenter Randomized Controlled Phase II Trial
